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Endometrial cancer is the most commonly diagnosed gynecological cancer in developed countries. Based on evidence from
observational studies which suggest selenium inhibits the development of several cancers (including lung and prostate cancer),
selenium supplementation has been touted as a potential cancer preventative agent. However, randomized controlled trials have
not reported benefit for selenium supplementation in reducing cancer risk. For endometrial cancer, limited observational studies
have been conducted assessing whether selenium intake, or blood selenium levels, associated with reduced risk, and no
randomized controlled trials have been conducted. We performed a two-sample Mendelian randomization analysis to examine the
relationship between selenium levels (using a composite measure of blood and toenail selenium) and endometrial cancer risk, using
summary statistics for four genetic variants associated with selenium levels at genome-wide significance levels (P < 5 × 10-8), from
a study of 12,906 endometrial cancer cases and 108,979 controls, all of European ancestry. Inverse variance weighted (IVW) analysis
indicated no evidence of a causal role for selenium levels in endometrial cancer development (OR per unit increase in selenium
levels Z-score = 0.99, 95% CI = 0.87-1.14). Similar results were observed for sensitivity analyses robust to the presence of unknown
pleiotropy (OR per unit increase in selenium levels Z-score = 0.98, 95% CI 0.89-1.08 for weighted median; OR per unit increase in
selenium levels Z-score = 0.90, 95% CI = 0.53-1.50 for MR-Egger). In conclusion, these results do not support the use of selenium
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Abstract 24 
Endometrial cancer is the most commonly diagnosed gynecological cancer in developed 25 
countries. Based on evidence from observational studies which suggest selenium inhibits the 26 
development of several cancers (including lung and prostate cancer), selenium 27 
supplementation has been touted as a potential cancer preventative agent. However, 28 
randomized controlled trials have not reported benefit for selenium supplementation in 29 
reducing cancer risk. For endometrial cancer, limited observational studies have been 30 
conducted assessing whether selenium intake, or blood selenium levels, associated with 31 
reduced risk, and no randomized controlled trials have been conducted. We performed a two-32 
sample Mendelian randomization analysis to examine the relationship between selenium 33 
levels (using a composite measure of blood and toenail selenium) and endometrial cancer 34 
risk, using summary statistics for four genetic variants associated with selenium levels at 35 
genome-wide significance levels (P < 5 × 10-8), from a study of 12,906 endometrial cancer 36 
cases and 108,979 controls, all of European ancestry. Inverse variance weighted (IVW) 37 
analysis indicated no evidence of a causal role for selenium levels in endometrial cancer 38 
development (OR per unit increase in selenium levels Z-score = 0.99, 95% CI = 0.87-1.14). 39 
Similar results were observed for sensitivity analyses robust to the presence of unknown 40 
pleiotropy (OR per unit increase in selenium levels Z-score = 0.98, 95% CI 0.89-1.08 for 41 
weighted median; OR per unit increase in selenium levels Z-score = 0.90, 95% CI = 0.53-42 
1.50 for MR-Egger). In conclusion, these results do not support the use of selenium 43 
supplementation to prevent endometrial cancer. 44 
 45 
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Endometrial cancer is the most commonly diagnosed cancer of the female reproductive 51 
system in developed countries (1). Unlike breast and cervical cancers where a screening 52 
program is available to the general population, there is currently no available screening test 53 
for endometrial cancer and diagnosis relies on biopsy in symptomatic patients (2). 54 
Furthermore, the incidence of endometrial cancer is rising (3), highlighting the need for 55 
preventative measures. Selenium has received considerable attention as a possible cancer 56 
preventive agent (reviewed in (4)). While randomized controlled trials have shown no benefit 57 
for selenium supplementation in reducing cancer risk over a period of up to eight years (5), 58 
some observational longitudinal studies assessing selenium intake or selenium levels, over a 59 
period up to 25 years, have shown an inverse association between selenium and cancer risk 60 
(reviewed in (4)). Thus, although findings from the longitudinal studies have been 61 
inconsistent (4), they may provide insight into the longer term effects of selenium exposure. 62 
A recent meta-analysis examining the association between selenium intake (dietary and 63 
supplemental) and overall cancer risk, has suggested that there was a reduction in cancer 64 
incidence among people consuming more than the recommended daily allowance of selenium 65 
(55 µg/day; RR = 0.96, 95% CI = 0.92-0.99)(6).  66 
 67 
Very few studies have assessed the effects of selenium on endometrial cancer. In terms of 68 
cellular studies, it has been shown that a selenium metabolite can inhibit endometrial cancer 69 
cell proliferation, potentially through disruption of estrogen signaling (7). Findings from 70 
human studies, however, have been more equivocal. A population-based, case-control 71 
observational study of 417 endometrial cancer cases and 395 controls specifically assessed 72 
the role of dietary and supplemental selenium intake (as measured by questionnaire in the six 73 
months prior to diagnosis or enrolment as a control) in endometrial cancer development (8). 74 
In a comparison of the highest (≥103.2 µg) and lowest (<72.4 µg) selenium quartiles, this 75 
study did not support an association between selenium intake and endometrial cancer risk 76 
(OR = 0.74, 95% CI = 0.47-1.17) (8). Two small case-control studies (n < 100) have assessed 77 
serum selenium levels in endometrial cancer cases and controls. Sundstrom et al (9) reported 78 
lower blood selenium levels in 64 cases as compared to 61 non-cancer controls, with an 79 
average of 1.01±0.05 v 1.40±0.08 µmol/L blood selenium in cases and controls respectively 80 
(P<0.001). A subsequent study of 35 endometrial cancer cases and 32 non-cancer controls 81 
reported a similar finding (average of 1.14±0.04 v 1.26±0.03 µmol/L blood selenium in cases 82 
and controls respectively, P<0.01)(10). Inconsistent results from these observational studies 83 
may be due to small sample sizes (8-10), reverse causation bias (9, 10), recall bias and 84 
measurement error in the dietary assessment (8). No prospective studies have examined the 85 
association of pre-diagnostic selenium levels with endometrial cancer risk. Thus, the role of 86 
selenium in endometrial cancer development remains inconclusive.  87 
 88 
As no intervention study has yet been performed to explore the role of selenium in 89 
endometrial cancer risk, we employed a two-sample Mendelian randomization approach 90 
which uses germline genetic variants associated with selenium levels to proxy for selenium 91 
exposure (11). These germline genetic variants are largely independent from environment or 92 
lifestyle factors, and are established prior to disease onset, thus analyses using these genetic 93 
variants as instrumental variables are less susceptible to biases from confounding and reverse 94 
causation. Further, genetic effects on exposure of interest are lifelong, and hence it is 95 
comparable to a lifelong randomized controlled trial.   96 
 97 





Summary statistics for twelve genetic variants associated with selenium levels at genome-99 
wide significance (P < 5×10-8) were extracted from a genome-wide association study 100 
(GWAS) meta-analysis of circulating selenium levels (n = 5,477; (12)) and toenail selenium 101 
levels (n = 4,162; (13)) in European-ancestry individuals. These variants were at two separate 102 
genetic loci; 5q14 (9 variants) and 21q22 (3 variants). To analyze the effect of selenium 103 
exposure on endometrial cancer risk, we used summary statistics from the Endometrial 104 
Cancer Association Consortium (ECAC) GWAS of 12,906 endometrial cancer cases and 105 
108,979 controls of European descent (14). One of the 5q14 selenium-associated genetic 106 
variants, rs558133, was excluded because it was not assessed by the ECAC GWAS (it does 107 
not appear on the 1000 Genomes v3 reference panel) and no proxy with r2 > 0.8 could be 108 
found.  These potential instrumental variables were pruned for linkage disequilibrium (LD; r2 109 
< 0.05) and four selenium-associated genetic variants (two independent variants per locus) 110 
remained as instrumental variables. We used PhenoScanner v2 (15) to explore the possibility 111 
of horizontal pleiotropy among the instrumental variables and their highly correlated variants 112 
(r2 > 0.8). Specifically, we examined traits associated with known risk factors of endometrial 113 
cancer (i.e. body mass index, age at menarche, age at menopause, postmenopausal serum 114 
estradiol levels, nulliparity, infertility and insulin levels) in the published literature at P < 115 
7.14×10-3 (i.e. 0.05/number of known risk factors explored, n=7); none of these instrumental 116 
variables were associated with these traits.  117 
 118 
The reported effect for circulating and toenail selenium instrumental variables was expressed 119 
in Z-score units per effect allele. For the purpose of Mendelian randomization analysis, Z-120 
scores were converted to beta and standard error values using the following equations, as per 121 
Taylor et al (16), where N is the sample size, eaf is the effect allele frequency and SE is the 122 










Converted selenium level summary statistics for these instrumental variables and their 127 
association with endometrial cancer risk are shown in Table 1.  Because summary statistics 128 
were expressed in Z-scores, neither the converted beta values for associations of genetic 129 
variants with selenium levels nor the effect sizes from the Mendelian randomization analysis 130 
have interpretable units, however they do provide the direction and statistical strength of 131 
associations. 132 
 133 
Individual Wald-type ratios for each of the instrumental variables were determined as a ratio 134 
of instrumental variable-endometrial cancer regression over the instrumental variable-135 
selenium levels regression (17). Individual Wald-type ratios were meta-analyzed using the 136 
inverse variance weighted (IVW) approach. A random effect model was used to account for 137 
heterogeneity. The IVW approach assumes that instrumental variables do not exhibit 138 
horizontal pleiotropy (where a single genetic variant has simultaneous effects on other 139 
phenotype(s) independently of the exposure of interestthat affect the outcome) or, if this is 140 
violated, that the horizontal pleiotropy is “balanced” across all instrumental variables. Thus, 141 
we implemented sensitivity analyses that are more robust to pleiotropy when it is 142 
“unbalanced” (i.e. exhibiting directional pleiotropy): (i) weighted median analysis, which 143 





variables with horizontal pleiotropic effects (18); and (ii) random effect MR-Egger analysis, 145 
which provides valid pleiotropy-corrected causal estimates even if all instrumental variables 146 
are invalid (19). MR-Egger analysis corrects for the directional pleiotropy by introducing an 147 
intercept which captures the average pleiotropic effects of all included variants on the 148 
outcome. An exponentiated MR-Egger intercept that deviates from 1 is an indicator of 149 
directional pleiotropy. It should also be noted that the validity of IVW and MR-Egger 150 
regression estimates rely on satisfaction of the InSIDE (instrument strength independent of 151 
direct effect) assumption where the instrument strength does not correlate with the horizontal 152 
pleiotropic effects on the outcome (19). 153 
 154 
To assess the strength of the instruments, F statistics and the proportion of variance (R2) in 155 
circulating and toenail selenium explained by instrumental variables were calculated as per 156 
Rees et al (20) and Yarmolinsky et al (21). We used the  (22) statistic to assess weak 157 
instrument bias for MR-Egger analysis using the “MendelianRandomization” package in R 158 
(23). This statistic quantifies the regression dilution bias due to violation of the NO 159 
Measurement Error (NOME; genetic associations with exposure of interest are measured 160 
without error) assumption. An  statistic approaching 1 indicates that violation of the 161 
NOME assumption does not substantially dilute the effect estimates of MR-Egger analysis 162 
towards a null association. Unless otherwise stated, Mendelian randomization analyses were 163 
performed using the “TwoSampleMR” package in R (24).  164 
 165 
Results 166 
The combined multi-allelic instrument explained 2.9% of the variation in circulating and 167 
toenail selenium levels. Individual Wald-type ratios and F statistics for instrumental variables 168 
are presented in Table 2. F statistics for these instrumental variables were all greater than 10 169 
(range 19.24 to 44.55) indicating instruments were unlikely to suffer from weak instrument 170 
bias. Mendelian randomization analysis did not support an association between selenium 171 
levels and endometrial cancer risk using the IVW method (OR per unit increase in selenium 172 
levels Z-score = 0.99, 95% CI = 0.87-1.14, P = 0.93). We found limited evidence for 173 
heterogeneity amongst the individual casual estimates for the included variants by Cochran’s 174 
Q statistic (25) (Cochrain’s Q statistics = 7.22, P = 0.07). The exponentiated intercept of MR-175 
Egger regression wasproduced an intercept of 1.03 (95% CI = 0.91-1.16, P = 0.72) and 176 
therefore provided no evidence of directional pleiotropy across the multi-allelic instrument.  177 
Further, the   statistic, quantifying weak instrument bias in the context of MR-Egger, was 178 
minimal ( = 92%). This suggests that any potential bias towards a null association as a 179 
result of NOME violation is ≤8%. Association estimates from sensitivity analyses (MR-Egger 180 
regression and weighted median analysis) were consistent with that reported by IVW analysis 181 
(OR per unit increase in selenium levels Z-score = 0.90, 95% CI = 0.53-1.50, P = 0.72 for 182 
MR-Egger; OR per unit increase in selenium levels Z-score = 0.98, 95% CI = 0.89-1.08, P = 183 
0.70 for weighted median).  184 
 185 
Discussion 186 
To our knowledge, this is the first Mendelian randomization study evaluating the effect of 187 
selenium on endometrial cancer.  This analysis does not support a causal relationship between 188 
selenium levels and endometrial cancer risk. However, given the fact that the combined 189 
multi-allelic instrument explains a small amount of the variance in circulating and toenail 190 
selenium levels (<3%), the power to detect a causal association in Mendelian randomization 191 
analysis may be limited and thus, we cannot rule out the possibility that genetically predicted 192 
selenium levels have some effect on endometrial cancer risk. This analysis should be 193 





larger GWAS studies. Further, statistical power for Mendelian randomization analyses may 195 
also be increased through the use of more precise effect estimates from larger GWAS of 196 
endometrial cancer. 197 
 198 
The validity of Mendelian randomization analysis holds under the condition that three 199 
important assumptions are fulfilled. These assumptions require that genetic variants chosen as 200 
instrumental variables are: 201 
  202 
1. Strongly associated with the exposure of interest 203 
2. Not associated with any confounder(s) that affects the relationship between the 204 
exposure of interest and outcome 205 
3. Not associated with outcome, independent of the exposure (i.e. no horizontal 206 
pleiotropy) 207 
 208 
Our instrumental variables have high F-statistics (greater than 10), thus fulfilling assumption 209 
1. Assumptions 2 and 3 are difficult to validate. We have attempted to minimize violation of 210 
assumption 2 by scanning associations of instrumental variables from the literature, finding 211 
none of the instrumental variables to be associated with known endometrial cancer risk 212 
factors. However, we are limited in exploring this assumption by the GWAS that have been 213 
conducted for these risk factors, and we cannot discount the possibility that associations 214 
between these variants and unknown endometrial cancer risk factors may exist. Sensitivity 215 
testing (by MR-Egger regression and weighted median analysis) has been used to address 216 
assumption 3 and we have not found evidence that this assumption has been violated. 217 
However, given the limitations of these tests (e.g. the low statistical power of the MR-Egger 218 
intercept test, discussed below), we cannot rule out this possibility. 219 
 220 
The strengths of our study include incorporation of multiple selenium level-associated 221 
genetic variants as a multi-allelic instrument to maximize the variation in selenium levels 222 
explained; and use of the largest available GWAS datasets to provide the greatest statistical 223 
power possible. Limitations of this study include use of instrumental variables from mixed 224 
gender GWAS which were assessed in female-only endometrial cancer GWAS. Although 225 
both selenium GWASs controlled for the effect of sex, we cannot not exclude the possibility 226 
that there is a residual effect of this covariate which may violate the assumption that 227 
instrumental variables are strongly associated with the exposure. Another potential limitation 228 
of two-sample Mendelian randomization is that by using two different GWAS sample sets to 229 
obtain the instrumental variable-exposure and -outcome effect, population stratification may 230 
have confounded the observedGWAS associations despite all populations being of European 231 
descent. Weaknesses of the MR-Egger regression sensitivity analysis performed in our study 232 
include its relatively lower statistical power as compared to the IVW and weighted median 233 
analysis methods, and its vulnerability to weak instrument bias which may bias MR-Egger 234 
regression towards the null (19). However, we assessed the extent to which weak instrument 235 
bias may have affected our MR-Egger results using the   statistic, and found it to be 236 
negligible.  237 
 238 
The identification of preventative agents for cancer is an attractive avenue of research 239 
because unlike other approaches for disease prevention, such as lifestyle changes, taking a 240 
dietary supplement (e.g. selenium) should be considerably easier to implement. Candidate 241 
dietary supplements can be identified by observational studies; however, moving these 242 
candidates through to human use requires the establishment of expensive randomized 243 
controlled trials. For example, a recent prostate cancer prevention trial, examining the benefit 244 




of selenium and/or vitamin E supplement on cancer risk, failed because of adverse effects and 245 
lack of efficacy, at a cost of >US$110 million (26, 27); whereas, a subsequent Mendelian 246 
randomization study was able to recapitulate the results of this trial using publicly available 247 
GWAS data (21).  248 
 249 
In conclusion, Mendelian randomization analysis provided no support for selenium 250 
supplementation in the prevention of endometrial cancer. More generally, these findings 251 
further highlight the value of Mendelian randomization for rapidly excluding proposed 252 
interventions that are unlikely to be successful, prior to the initiation of expensive and 253 
lengthy trials. This approach could allow resources to be targeted towards trials of alternative 254 
interventions with more promising genetic evidence. 255 
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Table 1. Genetic associations with selenium levels and endometrial cancer risk 365 
Instrumental 
Variables 
Chr:Pos* R2† EA OA EAFSe
Z-
score
BetaSe SESe PSe EAFEC BetaEC SEEC PEC 
rs1789953 chr21:44482936 
0.04 
T C 0.14 5.52 0.16 0.03 3.4×10-8 0.13 -0.04 0.02 0.12 
rs6586282 chr21:44478497 T C 0.17 -5.89 -0.16 0.03 3.96×10-9 0.17 -0.04 0.02 0.04 
rs6859667 chr5:78745042 
0.03 
T C 0.96 -6.92 -0.36 0.05 4.4×10-12 0.96 0.02 0.04 0.54 
rs921943 chr5:78316476 T C 0.29 13.14 0.29 0.02 1.9×10-39 0.29 0.00 0.02 0.90 
*from hg19; †pairwise LD in Europeans (1000 Genomes) provided for instrumental variables at the same locus; Se: Selenium; EC: Endometrial 366 
cancer; EA: Effect allele; OA: Other allele; EAF: Effect allele frequency from each GWAS; Beta: effect size; SE: Standard error; P: P-value. 367 
BetaEC and SEEC are the natural log odds ratio of endometrial cancer risk and associated standard error, respectively. Estimates for Selenium 368 
levels have been taken from (13) and estimates for EC from (14). 369 
 370 
Table 2. F statistics and Individual Wald-type ratios for all instrumental variables  371 
Instrumental 
variables 
F statistic BetaSe-EC SESe-EC PSe-EC 
rs1789953 34.07 -0.22 0.14 0.12 
rs6586282 36.88 0.26 0.13 0.04 
rs6859667 19.24 -0.07 0.11 0.54 
rs921943 44.55 -0.01 0.06 0.89 
Se: Selenium; EC: Endometrial cancer; Beta: effect size in standard deviation unit; SE: Standard error; P: P value 372 
 373 
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